A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers

Abstract Background To determine the effect of riociguat, an oral, selective soluble guanylate cyclase stimulator, on the net digital ulcer (DU) burden in systemic sclerosis (SSc). Methods Participants with SSc-related active or painful indeterminate DUs were recruited in a multicenter, double-blind...

Full description

Bibliographic Details
Main Authors: Vivek Nagaraja, Cathie Spino, Erica Bush, Pei-Suen Tsou, Robyn T. Domsic, Robert Lafyatis, Tracy Frech, Jessica K. Gordon, Virginia D. Steen, Dinesh Khanna
Format: Article
Language:English
Published: BMC 2019-09-01
Series:Arthritis Research & Therapy
Subjects:
Systemic sclerosis
Digital ulcers
Riociguat
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13075-019-1979-7

Internet

http://link.springer.com/article/10.1186/s13075-019-1979-7

Similar Items